Obtusin
Based on 1 Customer Validation
Obtusin is an orally active human monoamine oxidase A (hMAO-A) inhibitor discovered from the seeds of Cassia obtusifolia, with a Ki value of 6.15 μM. Obtusin inhibits high glucose-induced activation of the MAPKs/NF-κB/VEGF pathway and downregulates the expression of Poldip2, Nox4, VCAM-1, and HIF-1α, thereby alleviating oxidative stress, endothelial activation, and angiogenesis-related functions. Obtusin ameliorates diabetic retinopathy in vivo. Obtusin is used in research related to diabetes and neurodegenerative diseases (anxiety and depression).
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 99.10%
- CAS 番号: 70588-05-5
- 分子式: C18H16O7
- 分子量:344.32
-
保管条件:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
VEGFR アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
|
hMAO-A 11.12 μM (IC50) |
hMAO-A 6.15 μM (Ki) |
HIF-1α |
体外実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HRMECs
-
Concentration:10 and 20 μM
-
Incubation Time:48 h
-
Result:Determined 10 μM and 20 μM obtusin for 48 h as optimal conditions.
Dose-dependently suppressed proliferation and migration.
Inhibited tube-forming ability dose-dependently.
-
Cell Line:HRMECs
-
Concentration:10 and 20 μM
-
Incubation Time:2 h
-
Result:Significantly inhibited VEGFA mRNA expression.
Markedly reduced intracellular ROS levels.
Effectively reversed changes in Poldip2, Nox4, VCAM-1, and HIF-1α protein expression.
Reversed changes in MAPKs/NF-κB/VEGF pathway proteins (p-p38, p-p65, VEGFA).
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BLKS/J Lepr db mutant mice (seven-week-old, male)[1]
-
Dosage:5 and 10 mg/kg/day
-
Administration:p.o.; daily; 12 weeks
-
Result:Reduced blood glucose levels from weeks 12 to 20 and improved body weight by week 14.
Corrected abnormal lipid profiles by reducing serum TC, TG, and LDL levels at 20 weeks.
Reduced GCL edema, increased cell numbers in the INL and ONL, and improved retinal thickness and morphology.
Reduced vascular leaks, improved retinal vascular permeability, and diminished overall fluorescence intensity.
Significantly reduced pericyte loss and the formation of acellular capillaries.
Reduced ROS levels across all retinal layers.
Alleviated structural abnormalities in retinal ganglion cells and vascular endothelial cells in a dose-dependent manner.
Reduced glial cell activation (IBA1 and GFAP) and preserved ganglion cell numbers (BRN3A) in a dose-dependent manner.
Significantly reduced the elevated levels of iNOS, IL-1β, IL-6, and VEGFA in the retinas.
- RNA extraction experimental
- Human pluripotent stem cell endothelial-cell differentiation
- Vascular/Branching Fractal Analysis
- ROS/oxidative-stress fluorescent staining
- Endothelial Tube Formation Assay
- Research Protocol for Inflammation-related Diseases
- Research Protocol for Metabolic Diseases
- Endothelial Cell Migration/Angiogenic Sprouting Assay
化学情報
-
CAS 番号 70588-05-5
-
性状 Solid
-
分子量 344.32
-
分子式 C18H16O7
-
Color Yellow to orange
-
SMILES
O=C1C2=C(C=C(C)C(O)=C2OC)C(C3=CC(OC)=C(OC)C(O)=C13)=O
-
Structure Classification
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
溶剤 & 溶解度
体外:
DMSO : 5 mg/mL (14.52 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
純度とドキュメンテーション
-
データシート (291 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
取扱説明書 (2659 KB)
参考文献
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.9043 mL | 14.5214 mL | 29.0428 mL | 72.6069 mL |
| 5 mM | 0.5809 mL | 2.9043 mL | 5.8086 mL | 14.5214 mL | |
| 10 mM | 0.2904 mL | 1.4521 mL | 2.9043 mL | 7.2607 mL |